American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

AstraZeneca PLC

AZN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

AZN historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of AZN by members of U.S. Congress

Politician Type Traded
Alan Armstrong Senate / R Purchase $1,001 - $15,000 Mar 31, 2026
Alan Armstrong Senate / R Purchase $15,001 - $50,000 Mar 30, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 13, 2026
Ro Khanna House / D Sale $15,001 - $50,000 Feb 13, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec 18, 2025
Julia Letlow House / R Purchase $1,001 - $15,000 Dec 08, 2025
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Nov 19, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 31, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 30, 2025
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Oct 21, 2025
Val T. Hoyle House / D Sale $1,001 - $15,000 Sep 23, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jul 22, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Jun 17, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jun 09, 2025
Bruce Westerman House / R Sale $1,001 - $15,000 Apr 21, 2025
Bruce Westerman House / R Purchase $1,001 - $15,000 Mar 03, 2025
Val T. Hoyle House / D Purchase $1,001 - $15,000 Oct 29, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 13, 2023
Michael T. McCaul House / R Sale $50,001 - $100,000 Aug 14, 2023
Michael T. McCaul House / R Sale $100,001 - $250,000 Aug 14, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 11, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 Jul 31, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 Jul 31, 2023
Daniel S. Goldman House / D Sale $100,001 - $250,000 Jul 10, 2023
Michael T. McCaul House / R Sale $50,001 - $100,000 Jul 08, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 Jul 06, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 May 02, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 May 02, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 01, 2023
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 16, 2022
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 16, 2022
Michael T. McCaul House / R Purchase $50,001 - $100,000 Jun 05, 2022
Michael T. McCaul House / R Purchase $50,001 - $100,000 May 05, 2022
Michael T. McCaul House / R Purchase $100,001 - $250,000 Apr 28, 2022
Michael T. McCaul House / R Purchase $100,001 - $250,000 Apr 28, 2022
Ro Khanna House / D Sale $1,001 - $15,000 Dec 14, 2021
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Dec 01, 2021
Dean Phillips House / D Exchange $1,001 - $15,000 Jul 21, 2021
Sara Jacobs House / D Sale $15,001 - $50,000 Apr 09, 2021
Alan S. Lowenthal House / D Purchase $962.54 Feb 22, 2021
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Feb 22, 2021
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Feb 22, 2021
Greg Gianforte House / R Purchase $1,001 - $15,000 Dec 01, 2020
Thomas R. Suozzi House / D Sale $15,001 - $50,000 Feb 24, 2020
John H. Rutherford House / R Sale $1,001 - $15,000 Jan 15, 2020
Thomas R. Suozzi House / D Purchase $15,001 - $50,000 Jan 07, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 May 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May 28, 2019
AZN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
AZN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AZN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in AZN holdings by institutional investors

Insider Trading

Quarterly net insider trading by AZN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $1,680,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign) Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code
  • $2,280,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign)
  • $670,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
  • $1,350,000 Oct 17, 2025 Issue: Pharmacy Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
  • $1,840,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
  • $1,240,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $640,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Insurance
  • $650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
  • $830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
Revolving Door

Former government officials who have lobbied for AZN

63 former government officials from 38 congressional offices at 11 lobbying firms have lobbied for AZN, most recently Sep 16, 2026.

  • Jason Smith
    Matthew Schuck House New Communications Dir., House Budget Committee/Rep. Jason Smith; Communications Dir., Rep. Sean Duffy; Press Sec., Rep. Mark Sanford; Dir. of Strategic Communications, HUD; White House Liaison, USAGM Formerly with Jason Smith · THOLOS GOVERNMENT RELATIONS · Sep 16, 2026
  • Michael Williams House New Associate Deputy General Counsel, OMB; Deputy Asst. to President and Counselor to the White House Chief of Staff; Acting General Counsel, Department of Housing and Urban Development Formerly Associate Deputy General Counsel, OMB; Deputy Asst. to President and Counselor t · THOLOS GOVERNMENT RELATIONS · Sep 16, 2026
  • Lindsey Graham
    Aleix Jarvis Senate New Legislative Director, Senator Lindsey Graham; Legislative Director, Rep. Lindsey Graham; Legislative Assistant, Rep. Lindsey Graham; Staff Assistant, Rep. Charles Taylor Formerly with Lindsey Graham · THOLOS GOVERNMENT RELATIONS · Sep 16, 2026
  • Jason Smith
    Matthew Schuck House New Communications Dir., House Budget Committee/Rep. Jason Smith; Communications Dir., Rep. Sean Duffy; Press Sec., Rep. Mark Sanford; Dir. of Strategic Communications, HUD; White House Liaison, USAGM Formerly with Jason Smith · THOLOS GOVERNMENT RELATIONS · Sep 16, 2026
  • Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid Formerly Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Ad · TODD STRATEGY GROUP · Jul 20, 2026
  • John B. Shadegg
    Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg Formerly with John B. Shadegg · TODD STRATEGY GROUP · Jul 20, 2026
  • Brett Guthrie
    Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 20, 2026
  • Brett Guthrie
    Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 20, 2026
See all 63 on the Revolving Door dashboard
Corporate Lobbying

AZN Estimated quarterly lobbying spending

Revenue Breakdown

AZN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
AZN Income Statement
AZN Balance Sheet
AZN Cash Flow
U.S. Patents

New AZN patent grants

  • Patent Title: Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide Nov. 08, 2016
  • Patent Title: Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) Oct. 25, 2016
  • Patent Title: Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Oct. 18, 2016
  • Patent Title: Crystal structures of sglt2 inhibitors and processes for preparing same Sep. 27, 2016
  • Patent Title: Arginase inhibitors and methods of use thereof Sep. 20, 2016
  • Patent Title: Methods for improving asthma symptoms using benralizumab Sep. 13, 2016
  • Patent Title: Methods for increasing forced expiratory volume in asthmatics using benralizumab Sep. 13, 2016
  • Patent Title: Methods for reducing exacerbation rates of asthma using benralizumab Sep. 13, 2016
  • Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Aug. 30, 2016
  • Patent Title: Chemical compounds Aug. 23, 2016
  • Patent Title: Combinations comprising (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Aug. 02, 2016
  • Patent Title: Benzoxazinone amides as mineralocorticoid receptor modulators Jul. 19, 2016
  • Patent Title: Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor Jun. 28, 2016
  • Patent Title: Azaindole derivatives Jun. 21, 2016
  • Patent Title: Coated tablet formulation and method May. 17, 2016
  • Patent Title: Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits Apr. 12, 2016
  • Patent Title: Methods and compositions for treating asthma Mar. 29, 2016
  • Patent Title: Inhaler with indexing linked to movement of cover Mar. 22, 2016
  • Patent Title: Dispenser and method for entraining powder in an airflow Mar. 15, 2016
  • Patent Title: Inhaler 624 Feb. 09, 2016
  • Patent Title: Chemical compounds Feb. 02, 2016
  • Patent Title: Compounds and their use as bace inhibitors Feb. 02, 2016
  • Patent Title: Compound Dec. 29, 2015
  • Patent Title: Dispenser and method for entraining powder in an airflow Dec. 15, 2015
  • Patent Title: Pharmaceutical formulations containing an sglt2 inhibitor Dec. 01, 2015
  • Patent Title: Vial cap 187 Nov. 03, 2015
  • Patent Title: Inhaler comprising a base having a plurality of medicament containing sealed cavities Nov. 03, 2015
  • Patent Title: Chemical compounds Oct. 13, 2015
  • Patent Title: Breath activated inhaler Oct. 13, 2015
  • Patent Title: Chemical compounds Oct. 13, 2015
  • Patent Title: Chemical compounds Oct. 13, 2015
  • Patent Title: Crystalline naloxol-peg conjugate Oct. 06, 2015
  • Patent Title: Bis-(sulfonylamino) derivatives for use in therapy Sep. 29, 2015
  • Patent Title: Ticagrelor co-crystal Aug. 11, 2015
  • Patent Title: Inhalation device and method of dispensing medicament Aug. 04, 2015
  • Patent Title: Process for the preparation of benzyl [(3as,4r,6s,6ar)-6-hydroxy-2,2-dimethyltetrahydro-3ah-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process Jul. 14, 2015
  • Patent Title: Inhibitors of protein kinases Jun. 30, 2015
  • Patent Title: Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor Jun. 30, 2015
  • Patent Title: Medicament-containing dispenser provided with a display for presenting indicia to a user Jun. 16, 2015
  • Patent Title: Bilayer tablet formulations Jun. 09, 2015
  • Patent Title: Imidazoquinoline compounds Jun. 02, 2015
  • Patent Title: Melanocortin receptor-specific peptides May. 26, 2015
  • Patent Title: Quinazoline derivatives as vegf inhibitors May. 26, 2015
  • Patent Title: Chemical compounds 542 May. 26, 2015
  • Patent Title: Ethanamine compounds and methods of using the same May. 19, 2015
  • Patent Title: Cyclopropyl amide derivatives May. 12, 2015
  • Patent Title: Chromenone derivatives May. 12, 2015
  • Patent Title: Chemical compounds Apr. 28, 2015
  • Patent Title: Phosphonoxy quinazoline derivatives and their pharmaceutical use Apr. 28, 2015
  • Patent Title: Crystalline naloxol-peg conjugate Apr. 21, 2015
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to AZN from public contracts

AZN News

Recent insights relating to AZN

CNBC Recommendations

Recent picks made for AZN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AZN

AZN Analyst Ratings

AZN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
AZN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $AZN stock a Buy, Sell, or Hold?

  • What is the price target for $AZN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

AZN Top Shareholders
Shareholder
Shares Held
AZN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $AZN stock?

  • Who owns the most shares of $AZN stock?

  • What funds own $AZN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AZN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AZN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About AZN

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

AstraZeneca PLC (AZN) Historical Stock Prices

AstraZeneca PLC (AZN) closed at $168.37 on September 22, 2026. Over the past year its adjusted close ranged from $144.58 to $207.09. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month+1.44%
  • 3 months-6.38%
  • Year to date-6.85%
  • 1 year+10.49%
  • 3 years+32.62%
  • 5 years+58.21%
  • Max+365.07%
See every congressional and insider trade on the AZN price chart

Quiver Premium charts AZN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 167.84 169.35 166.74 168.37 168.37 2,306,260
Sep 21, 2026 168.45 169.00 167.11 168.10 168.10 2,937,798
Sep 18, 2026 167.15 167.83 165.54 166.08 166.08 3,060,377
Sep 17, 2026 164.59 166.29 164.29 166.14 166.14 3,807,907
Sep 16, 2026 164.21 165.42 162.02 162.89 162.89 3,859,290
Sep 15, 2026 161.42 163.90 160.71 161.85 161.85 2,939,384
Sep 14, 2026 164.08 164.55 162.14 163.78 163.78 3,093,646
Sep 11, 2026 161.43 161.51 158.13 160.17 160.17 2,229,337
Sep 10, 2026 157.68 160.30 157.23 159.64 159.64 2,935,497
Sep 9, 2026 158.31 159.13 156.74 156.94 156.94 3,874,039
Sep 8, 2026 163.96 163.96 159.40 160.04 160.04 5,146,269
Sep 4, 2026 162.82 163.78 161.13 162.70 162.70 3,073,349
Sep 3, 2026 165.64 165.74 162.24 164.77 164.77 2,425,270
Sep 2, 2026 162.54 164.69 160.87 161.63 161.63 3,301,432
Sep 1, 2026 163.66 164.24 161.38 162.47 162.47 2,598,488
Aug 31, 2026 162.70 163.75 161.95 162.13 162.13 3,068,214
Aug 28, 2026 163.52 163.54 161.18 162.70 162.70 2,880,828
Aug 27, 2026 165.27 165.58 163.98 164.52 164.52 2,495,241
Aug 26, 2026 167.46 167.89 165.17 166.27 166.27 2,680,819
Aug 25, 2026 167.08 170.18 166.78 169.66 169.66 3,453,733
Aug 24, 2026 164.57 167.08 163.97 166.71 166.71 2,780,179
Aug 21, 2026 164.04 167.25 163.96 165.98 165.98 3,179,849
Aug 20, 2026 163.40 165.57 161.47 164.49 164.49 5,094,227
Aug 19, 2026 162.13 165.91 162.00 164.95 164.95 3,817,873
Aug 18, 2026 159.12 160.64 158.98 160.10 160.10 3,001,597
Aug 17, 2026 156.30 157.26 155.78 156.89 156.89 3,361,580
Aug 14, 2026 155.50 156.46 154.53 156.45 156.45 3,697,884
Aug 13, 2026 157.85 158.44 156.97 157.24 157.24 3,598,337
Aug 12, 2026 157.68 159.02 157.12 158.50 158.50 4,140,378
Aug 11, 2026 162.06 162.26 158.61 158.75 158.75 2,754,804
Aug 10, 2026 160.59 162.72 160.25 161.91 161.91 3,745,981
Aug 7, 2026$1.06 dividend 162.14 162.18 160.00 161.42 161.42 3,720,555
Aug 6, 2026 162.62 162.93 159.75 161.07 160.02 2,353,906
Aug 5, 2026 163.79 164.45 160.72 161.50 160.45 7,002,933
Aug 4, 2026 157.95 158.56 155.32 155.62 154.60 8,095,273
Aug 3, 2026 157.16 159.72 153.41 157.97 156.94 16,313,046
Jul 31, 2026 170.53 170.74 168.44 169.64 168.53 1,670,008
Jul 30, 2026 170.31 171.89 169.85 171.34 170.22 2,260,657
Jul 29, 2026 174.24 175.03 172.63 173.30 172.17 2,252,203
Jul 28, 2026 170.69 174.44 170.67 172.48 171.35 4,740,936
Jul 27, 2026 170.08 173.24 167.79 169.64 168.53 3,861,406
Jul 24, 2026 169.84 170.26 168.33 169.26 168.16 2,009,992
Jul 23, 2026 166.37 169.49 166.04 168.27 167.17 2,394,069
Jul 22, 2026 170.64 170.89 168.47 169.73 168.62 1,683,822
Jul 21, 2026 165.35 169.43 164.81 169.34 168.24 1,986,357
Jul 20, 2026 168.46 168.65 164.06 164.52 163.45 2,552,981
Jul 17, 2026 168.15 170.31 167.15 168.90 167.80 1,981,328
Jul 16, 2026 167.97 170.37 167.25 169.29 168.19 3,018,322
Jul 15, 2026 166.22 169.57 166.21 168.37 167.27 2,938,306
Jul 14, 2026 167.36 168.10 164.45 164.50 163.43 3,605,456
Jul 13, 2026 168.75 170.47 168.11 169.47 168.36 4,666,131
Jul 10, 2026 175.49 175.88 171.42 171.61 170.49 3,596,861
Jul 9, 2026 173.45 180.21 172.76 178.49 177.33 6,648,956
Jul 8, 2026 189.95 191.48 188.66 189.28 188.04 1,967,847
Jul 7, 2026 192.98 193.79 191.60 193.12 191.86 2,130,028
Jul 6, 2026 190.20 190.24 186.24 190.16 188.92 1,872,031
Jul 2, 2026 189.52 196.41 189.17 195.15 193.88 2,379,657
Jul 1, 2026 187.07 187.65 183.49 183.86 182.66 2,115,466
Jun 30, 2026 190.31 190.46 186.16 189.62 188.38 2,598,709
Jun 29, 2026 189.25 191.13 188.45 190.95 189.70 1,644,471
Jun 26, 2026 184.28 189.57 184.28 188.41 187.18 3,235,391
Jun 25, 2026 184.82 186.58 184.55 185.68 184.47 1,826,301
Jun 24, 2026 183.40 184.61 182.19 183.02 181.83 2,377,682
Jun 23, 2026 179.81 181.15 179.28 181.02 179.84 1,503,883
Jun 22, 2026 175.29 177.43 175.11 176.43 175.28 1,489,610
Jun 18, 2026 177.67 177.80 173.66 174.93 173.79 1,667,045
Jun 17, 2026 178.70 180.44 177.65 177.89 176.73 1,868,663
Jun 16, 2026 178.32 179.12 176.63 178.71 177.54 1,895,809
Jun 15, 2026 179.16 179.22 176.55 177.27 176.11 1,329,084
Jun 12, 2026 182.53 182.70 178.59 178.75 177.58 2,394,262
Jun 11, 2026 181.36 183.67 180.39 182.28 181.09 1,749,432
Jun 10, 2026 180.94 181.72 177.88 178.96 177.79 2,129,693
Jun 9, 2026 181.73 183.81 181.16 183.43 182.23 1,963,805
Jun 8, 2026 184.16 185.31 181.36 181.55 180.37 2,040,149
Jun 5, 2026 184.02 186.12 184.02 185.95 184.74 2,346,131
Jun 4, 2026 180.58 183.37 180.24 181.80 180.61 2,030,356
Jun 3, 2026 174.60 177.56 174.60 176.28 175.13 2,396,976
Jun 2, 2026 179.10 179.56 176.03 177.45 176.29 2,035,193
Jun 1, 2026 182.72 183.23 179.62 179.71 178.54 2,892,911
May 29, 2026 185.99 187.10 184.65 185.67 184.46 1,499,235
May 28, 2026 183.79 186.46 183.35 185.33 184.12 2,059,575
May 27, 2026 187.43 188.72 185.38 185.65 184.44 2,121,835
May 26, 2026 188.26 188.61 186.74 187.19 185.97 1,412,137
May 22, 2026 188.22 189.08 186.44 187.03 185.81 2,120,800
May 21, 2026 185.84 191.50 184.98 189.75 188.51 2,192,674
May 20, 2026 186.69 188.31 185.73 187.46 186.24 1,803,544
May 19, 2026 184.70 186.36 184.19 184.64 183.44 1,616,818
May 18, 2026 183.43 184.74 182.67 183.92 182.72 1,225,224
May 15, 2026 183.25 183.44 180.55 181.58 180.40 1,379,471
May 14, 2026 186.69 186.70 184.70 184.96 183.75 1,027,756
May 13, 2026 183.36 187.78 183.33 187.72 186.50 1,733,046
May 12, 2026 183.01 185.82 182.70 184.54 183.34 1,596,094
May 11, 2026 183.79 185.81 181.72 181.86 180.67 2,106,701
May 8, 2026 182.71 183.55 181.58 182.85 181.66 1,910,488
May 7, 2026 184.37 184.37 181.03 182.52 181.33 2,749,511
May 6, 2026 184.53 185.61 183.55 184.92 183.71 1,953,704
May 5, 2026 181.48 181.98 180.00 181.24 180.06 2,459,981
May 4, 2026 184.36 185.19 182.80 183.46 182.26 1,170,156
May 1, 2026 185.45 187.18 184.01 184.74 183.53 1,793,655
Apr 30, 2026 188.47 190.00 186.87 187.37 186.15 2,797,434
Apr 29, 2026 183.93 187.00 181.73 185.20 183.99 4,443,017
Apr 28, 2026 186.91 187.97 185.41 186.68 185.46 2,837,504
Apr 27, 2026 188.91 190.59 187.20 187.51 186.29 2,102,078
Apr 24, 2026 189.15 189.94 187.56 189.75 188.51 2,388,277
Apr 23, 2026 195.21 196.64 191.81 192.30 191.04 2,179,282
Apr 22, 2026 196.55 196.65 194.80 194.81 193.54 1,578,964
Apr 21, 2026 198.85 198.99 195.77 195.78 194.50 2,130,707
Apr 20, 2026 202.81 203.37 200.67 200.69 199.38 1,104,552
Apr 17, 2026 202.81 205.30 202.55 204.80 203.46 1,241,363
Apr 16, 2026 201.44 201.80 199.99 200.47 199.16 1,414,401
Apr 15, 2026 204.20 204.39 199.50 201.21 199.90 1,657,894
Apr 14, 2026 202.55 204.73 202.07 204.38 203.05 2,257,584
Apr 13, 2026 202.48 203.18 200.69 202.24 200.92 1,724,282
Apr 10, 2026 207.30 207.30 203.82 204.03 202.70 1,565,792
Apr 9, 2026 202.63 206.50 201.97 204.99 203.65 1,239,244
Apr 8, 2026 205.45 206.73 203.66 204.27 202.94 2,282,879
Apr 7, 2026 198.71 202.00 196.95 200.81 199.50 2,451,170
Apr 6, 2026 204.75 204.75 202.73 202.83 201.51 1,554,659
Apr 2, 2026 199.78 204.34 199.23 203.49 202.16 2,049,295
Apr 1, 2026 198.89 201.74 198.72 200.73 199.42 2,158,620
Mar 31, 2026 194.85 197.27 193.55 197.22 195.93 2,759,743
Mar 30, 2026 193.83 194.64 192.61 193.88 192.62 2,114,260
Mar 27, 2026 190.88 192.97 187.95 188.42 187.19 2,762,995
Mar 26, 2026 185.07 186.81 182.79 183.40 182.20 1,850,298
Mar 25, 2026 187.67 188.72 186.44 187.14 185.92 1,483,981
Mar 24, 2026 182.63 186.22 182.39 185.78 184.57 1,596,240
Mar 23, 2026 183.86 186.78 183.76 184.07 182.87 2,009,404
Mar 20, 2026 188.14 188.40 182.62 183.60 182.40 2,068,001
Mar 19, 2026 186.73 189.79 186.33 188.93 187.70 1,469,956
Mar 18, 2026 190.67 190.73 187.56 188.42 187.19 1,174,457
Mar 17, 2026 193.96 193.96 190.95 191.29 190.04 1,455,582
Mar 16, 2026 190.81 192.51 190.54 192.01 190.76 1,828,861
Mar 13, 2026 192.64 193.65 189.43 189.90 188.66 1,429,046
Mar 12, 2026 193.91 193.92 190.96 192.50 191.24 2,154,780
Mar 11, 2026 194.22 194.83 192.31 193.31 192.05 1,416,810
Mar 10, 2026 196.72 198.09 194.81 194.99 193.72 1,658,298
Mar 9, 2026 190.33 195.79 189.35 194.95 193.68 1,875,079
Mar 6, 2026 194.01 194.83 192.76 194.22 192.95 1,473,886
Mar 5, 2026 199.40 199.52 195.26 197.52 196.23 2,648,591
Mar 4, 2026 203.22 203.29 200.55 201.53 200.22 2,911,154
Mar 3, 2026 200.00 201.99 197.10 201.76 200.44 2,733,125
Mar 2, 2026 205.64 206.30 203.34 203.73 202.40 1,718,825
Feb 27, 2026 207.27 209.93 206.95 208.45 207.09 1,996,353
Feb 26, 2026 204.98 205.16 202.64 203.98 202.65 2,250,416
Feb 25, 2026 206.75 207.55 205.30 205.79 204.45 1,434,786
Feb 24, 2026 208.99 209.35 206.49 206.61 205.26 1,710,971
Feb 23, 2026 204.60 207.34 204.22 204.94 203.60 1,816,259
Feb 20, 2026$2.153 dividend 206.60 207.69 204.05 204.20 202.87 1,592,684
Feb 19, 2026 208.75 208.95 205.72 208.62 205.10 2,037,183
Feb 18, 2026 212.66 212.71 207.52 208.67 205.15 2,604,191
Feb 17, 2026 208.10 211.27 207.85 209.48 205.94 2,287,817
Feb 13, 2026 205.64 206.71 204.09 205.55 202.08 2,504,807
Feb 12, 2026 202.52 205.86 202.10 204.52 201.07 2,723,911
Feb 11, 2026 200.08 204.92 199.19 204.76 201.30 3,484,048
Feb 10, 2026 194.02 195.90 190.60 193.40 190.13 2,726,807
Feb 9, 2026 191.80 192.76 187.06 188.01 184.84 3,030,835
Feb 6, 2026 190.46 193.97 188.49 193.03 189.77 3,117,634
Feb 5, 2026 187.07 190.67 186.58 187.16 184.00 3,380,548
Feb 4, 2026 189.06 190.70 186.32 187.45 184.28 3,889,197
Feb 3, 2026 187.61 190.72 183.63 184.32 181.21 2,659,669
Feb 2, 20261-for-2 reverse split 187.50 192.79 186.18 188.41 185.23 3,228,784
Jan 30, 2026 93.03 93.51 92.46 92.77 182.41 5,555,024
Jan 29, 2026 93.37 93.53 92.57 92.59 182.05 6,475,002
Jan 28, 2026 93.17 93.83 92.90 93.22 183.29 8,234,272
Jan 27, 2026 94.65 96.18 94.65 95.60 187.97 7,052,743
Jan 26, 2026 93.14 94.58 93.08 94.23 185.28 6,108,189
Jan 23, 2026 92.06 92.98 91.44 92.95 182.76 4,322,864
Jan 22, 2026 90.45 91.79 90.17 91.69 180.28 6,145,218
Jan 21, 2026 89.68 90.78 89.04 90.54 178.02 9,116,010
Jan 20, 2026 90.14 91.11 89.17 89.94 176.84 11,137,317
Jan 16, 2026 94.47 94.68 93.51 94.39 185.59 55,050,701
Jan 15, 2026 95.30 95.36 93.41 93.99 184.81 9,146,674
Jan 14, 2026 96.02 96.43 95.37 96.34 189.43 7,709,315
Jan 13, 2026 94.14 94.53 92.78 94.51 185.83 8,037,234
Jan 12, 2026 95.14 95.18 93.41 93.63 184.10 10,755,466
Jan 9, 2026 95.24 95.94 94.53 94.65 186.10 6,077,499
Jan 8, 2026 95.18 95.94 93.22 94.01 184.84 5,616,391
Jan 7, 2026 94.81 96.51 94.12 95.16 187.11 6,615,153
Jan 6, 2026 92.49 95.27 92.46 94.96 186.71 6,325,025
Jan 5, 2026 91.17 91.38 89.53 91.22 179.36 5,908,778
Jan 2, 2026 92.39 92.45 91.17 91.57 180.05 3,563,352
Dec 31, 2025 92.25 92.48 91.92 91.93 180.75 2,097,318
Dec 30, 2025 92.66 92.88 92.36 92.51 181.90 1,730,525
Dec 29, 2025 92.33 92.89 92.33 92.52 181.91 2,371,767
Dec 26, 2025 92.53 92.91 92.18 92.90 182.66 1,669,376
Dec 24, 2025 92.32 92.61 92.01 92.45 181.78 1,184,654
Dec 23, 2025 92.52 93.10 91.94 92.14 181.17 3,544,381
Dec 22, 2025 90.81 91.86 90.63 91.55 180.01 4,648,995
Dec 19, 2025 90.43 91.87 90.36 91.36 179.63 8,374,375
Dec 18, 2025 90.28 91.17 90.19 90.61 178.16 6,828,550
Dec 17, 2025 91.09 91.25 89.85 89.86 176.69 5,975,458
Dec 16, 2025 90.87 91.58 90.19 91.35 179.61 4,514,854
Dec 15, 2025 90.37 91.79 90.12 91.56 180.03 7,020,702
Dec 12, 2025 89.40 89.96 89.28 89.83 176.63 5,377,260
Dec 11, 2025 90.62 91.52 90.19 90.29 177.53 6,628,233
Dec 10, 2025 91.18 91.66 89.70 91.51 179.93 6,119,915
Dec 9, 2025 91.18 91.44 89.78 89.82 176.61 4,728,134
Dec 8, 2025 90.36 91.36 89.67 91.28 179.48 7,055,475
Dec 5, 2025 90.69 91.18 90.06 90.18 177.31 5,432,911
Dec 4, 2025 90.65 90.87 89.77 90.03 177.02 5,250,861
Dec 3, 2025 90.69 91.28 90.52 90.85 178.63 6,837,023
Dec 2, 2025 90.91 91.08 90.14 90.17 177.29 6,504,867
Dec 1, 2025 92.94 92.98 90.42 90.52 177.98 6,366,644
Nov 28, 2025 92.57 92.83 92.05 92.72 182.31 3,747,969
Nov 26, 2025 93.00 94.02 92.84 93.32 183.49 4,656,384
Nov 25, 2025 92.44 93.41 92.20 93.24 183.33 5,425,913
Nov 24, 2025 90.61 91.83 90.61 91.52 179.95 5,726,213
Nov 21, 2025 89.34 91.91 89.34 91.00 178.93 7,402,348
Nov 20, 2025 89.85 90.01 88.41 88.68 174.36 5,863,236
Nov 19, 2025 89.56 90.06 88.59 88.99 174.97 6,439,194
Nov 18, 2025 89.03 89.70 88.44 89.55 176.07 6,357,880
Nov 17, 2025 89.33 90.27 89.11 89.40 175.78 3,814,139
Nov 14, 2025 88.52 89.37 88.28 89.10 175.19 4,090,547
Nov 13, 2025 87.89 89.43 87.62 88.61 174.23 4,514,764
Nov 12, 2025 88.27 88.90 87.23 87.68 172.40 5,231,592
Nov 11, 2025 88.19 89.31 88.00 89.09 175.17 4,963,456
Nov 10, 2025 86.24 87.53 85.84 87.48 172.00 6,271,748
Nov 7, 2025 84.55 85.15 84.22 84.58 166.30 4,106,122
Nov 6, 2025 84.31 85.02 83.37 83.77 164.71 6,942,147
Nov 5, 2025 81.38 82.09 81.02 81.15 159.56 5,448,786
Nov 4, 2025 80.65 82.11 80.48 82.03 161.29 4,673,213
Nov 3, 2025 81.98 82.40 81.05 81.72 160.68 2,896,549
Oct 31, 2025 82.18 82.55 81.50 82.40 162.02 2,977,722
Oct 30, 2025 82.09 82.82 81.29 82.34 161.90 5,791,262
Oct 29, 2025 83.39 83.46 81.64 82.23 161.68 3,570,044
Oct 28, 2025 84.04 84.22 81.78 82.61 162.43 3,661,749
Oct 27, 2025 83.46 84.21 83.23 84.06 165.28 6,247,961
Oct 24, 2025 83.45 83.52 82.92 83.29 163.77 2,380,453
Oct 23, 2025 83.17 83.81 83.12 83.40 163.98 2,149,848
Oct 22, 2025 83.45 84.21 83.28 83.43 164.04 3,313,353
Oct 21, 2025 83.84 83.91 83.12 83.22 163.63 5,616,670
Oct 20, 2025 84.86 85.18 83.78 83.87 164.91 5,016,376
Oct 17, 2025 83.83 85.06 83.65 84.69 166.52 3,125,960
Oct 16, 2025 83.52 84.42 83.09 83.83 164.83 4,326,064
Oct 15, 2025 83.55 85.04 83.53 84.83 166.79 4,070,016
Oct 14, 2025 84.58 85.17 84.30 85.12 167.37 4,902,168
Oct 13, 2025 84.35 84.92 84.05 84.51 166.16 5,979,944
Oct 10, 2025 85.63 85.88 83.84 84.53 166.21 14,476,330
Oct 9, 2025 85.90 86.38 84.99 85.04 167.21 9,093,484
Oct 8, 2025 86.35 86.48 85.16 85.38 167.88 6,621,301
Oct 7, 2025 85.42 86.24 85.35 85.87 168.84 3,492,741
Oct 6, 2025 85.54 86.57 85.14 85.49 168.09 6,384,890
Oct 3, 2025 84.30 85.50 83.84 85.31 167.74 5,869,288
Oct 2, 2025 83.40 84.05 82.88 83.65 164.47 5,451,241
Oct 1, 2025 81.03 84.61 80.82 84.36 165.87 14,451,418
Sep 30, 2025 74.43 76.99 73.96 76.72 150.85 7,682,597
Sep 29, 2025 74.19 74.68 73.69 74.13 145.76 6,118,738
Sep 26, 2025 73.67 74.06 73.33 73.76 145.03 4,345,423
Sep 25, 2025 74.57 74.69 72.89 73.53 144.58 4,886,408
Sep 24, 2025 75.20 75.66 74.92 75.36 148.17 3,092,991
Sep 23, 2025 76.61 76.86 75.90 75.97 149.37 3,912,871
Sep 22, 2025 76.67 77.89 76.58 77.50 152.38 4,870,404

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
AstraZeneca PLC Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at AZN, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation